

# Jiri Vencovsky

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2802271/jiri-vencovsky-publications-by-year.pdf>

**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

284 papers	19,583 citations	56 h-index	138 g-index
387 ext. papers	25,385 ext. citations	3.7 avg, IF	6.77 L-index

#	Paper	IF	Citations
284	Hsp90 Levels in Idiopathic Inflammatory Myopathies and Their Association With Muscle Involvement and Disease Activity: A Cross-Sectional and Longitudinal Study.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 811045	8.4	0
283	MyomiRs in cultured muscle cells from patients with idiopathic inflammatory myopathy are modulated by disease but not by 6-month exercise training. <i>Clinical and Experimental Rheumatology</i> , <b>2022</b> , 40, 346-357	2.2	
282	The beneficial effect of csDMARDs co-medication on drug persistence of first-line TNF inhibitor in rheumatoid arthritis patients: data from Czech ATTRa registry.. <i>Rheumatology International</i> , <b>2022</b> , 42, 803	3.6	0
281	MyomiRs in cultured muscle cells from patients with idiopathic inflammatory myopathy are modulated by disease but not by 6-month exercise training.. <i>Clinical and Experimental Rheumatology</i> , <b>2022</b> , 40, 346-357	2.2	
280	Idiopathic inflammatory myopathies. <i>Nature Reviews Disease Primers</i> , <b>2021</b> , 7, 86	51.1	7
279	IL-40: A New B Cell-Associated Cytokine Up-Regulated in Rheumatoid Arthritis Decreases Following the Rituximab Therapy and Correlates With Disease Activity, Autoantibodies, and NETosis. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 745523	8.4	0
278	S100A11 (calgizzarin) is released via NETosis in rheumatoid arthritis (RA) and stimulates IL-6 and TNF secretion by neutrophils. <i>Scientific Reports</i> , <b>2021</b> , 11, 6063	4.9	3
277	Circulating miR-145 as a marker of therapeutic response to anti-TNF therapy in patients with ankylosing spondylitis. <i>Physiological Research</i> , <b>2021</b> , 70, 255-264	2.1	0
276	Sexual function in patients with idiopathic inflammatory myopathies: a cross-sectional study. <i>Rheumatology</i> , <b>2021</b> , 60, 5060-5072	3.9	0
275	Clinical Trials in Myositis: Where Do We Stand?. <i>Current Treatment Options in Rheumatology</i> , <b>2021</b> , 7, 222-242	1.3	
274	The pre-clinical phase of rheumatoid arthritis: From risk factors to prevention of arthritis. <i>Autoimmunity Reviews</i> , <b>2021</b> , 20, 102797	13.6	14
273	The effect of a 24-week training focused on activities of daily living, muscle strengthening, and stability in idiopathic inflammatory myopathies: a monocentric controlled study with follow-up. <i>Arthritis Research and Therapy</i> , <b>2021</b> , 23, 173	5.7	2
272	Inhibition of Hsp90 Counteracts the Established Experimental Dermal Fibrosis Induced by Bleomycin. <i>Biomedicines</i> , <b>2021</b> , 9,	4.8	1
271	Clusterin serum levels are elevated in patients with early rheumatoid arthritis and predict disease activity and treatment response. <i>Scientific Reports</i> , <b>2021</b> , 11, 11525	4.9	3
270	Altered dynamics of lipid metabolism in muscle cells from patients with idiopathic inflammatory myopathy is ameliorated by 6 months of training. <i>Journal of Physiology</i> , <b>2021</b> , 599, 207-229	3.9	2
269	The dysregulation of monocyte subpopulations in individuals at risk of developing rheumatoid arthritis. <i>Rheumatology</i> , <b>2021</b> , 60, 1823-1831	3.9	1
268	Interleukin-35 in idiopathic inflammatory myopathies. <i>Cytokine</i> , <b>2021</b> , 137, 155350	4	1

267	Switching first-line targeted therapy after not reaching low disease activity within 6 months is superior to conservative approach: a propensity score-matched analysis from the ATTRA registry. <i>Arthritis Research and Therapy</i> , <b>2021</b> , 23, 11	5.7	4
266	Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study. <i>Scientific Reports</i> , <b>2021</b> , 11, 1	4.9	2785
265	High miR-451 expression in peripheral blood mononuclear cells from subjects at risk of developing rheumatoid arthritis. <i>Scientific Reports</i> , <b>2021</b> , 11, 4719	4.9	1
264	Polymyositis: does it really exist as a distinct clinical subset?. <i>Current Opinion in Rheumatology</i> , <b>2021</b> , 33, 537-543	5.3	2
263	Idiopathic inflammatory myopathies - new advances. <i>Neurologie Pro Praxi</i> , <b>2021</b> , 21, 477-484	0.2	
262	Plasma heat shock protein 90 levels in patients with spondyloarthritis and their relation to structural changes: a cross-sectional study. <i>Biomarkers in Medicine</i> , <b>2021</b> , 15, 5-13	2.3	2
261	Clusterin is upregulated in serum and muscle tissue in idiopathic inflammatory myopathies and associates with clinical disease activity and cytokine profile. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 1021-1032	2.2	1
260	Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , <b>2020</b> , 49, 361-370	1.9	
259	Alterations in activin A-myostatin-follistatin system associate with disease activity in inflammatory myopathies. <i>Rheumatology</i> , <b>2020</b> , 59, 2491-2501	3.9	9
258	S100A4 is elevated in axial spondyloarthritis: a potential link to disease severity. <i>BMC Rheumatology</i> , <b>2020</b> , 4, 13	2.9	0
257	Patients with Rheumatoid Arthritis Acquire Sustainable Skills for Home Monitoring: A Prospective Dual-country Cohort Study (ELECTOR Clinical Trial I). <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 658-667	4.1	3
256	SAT0324 SEXUAL HEALTH IN WOMEN AND MEN WITH SYSTEMIC SCLEROSIS: A CROSS-SECTIONAL STUDY. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1107.2-1108	2.4	1
255	Elevated Tenascin-C Serum Levels in Patients With Axial Spondyloarthritis. <i>Physiological Research</i> , <b>2020</b> , 69, 653-660	2.1	0
254	Clinical Features of Myositis: Muscular Manifestations <b>2020</b> , 37-46		1
253	FRI0041 ULTRASOUND-DETECTED SYNOVITIS AMONG INDIVIDUALS AT RISK OF RHEUMATOID ARTHRITIS INCREASES THE RISK OF DEVELOPING CLINICAL ARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 595-596	2.4	
252	THU0365 INCREASED HSP90 IN MUSCLE TISSUE AND PLASMA ASSOCIATES WITH DISEASE ACTIVITY AND SKELETAL MUSCLE INVOLVEMENT IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 414.1-414	2.4	
251	FRI0002 S100A11 (CALGIZZARIN) IS RELEASED DURING NEUTROPHIL EXTRACELLULAR TRAPS FORMATION AND STIMULATES RELEASE OF IL-6 AND TNF IN RHEUMATOID ARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 572.3-572	2.4	
250	AB1233 GENDER DIFFERENCE IN DISEASE SEVERITY AND TREATMENT OUTCOMES AMONG PATIENTS WITH RHEUMATOID ARTHRITIS (RA), AXIAL SPONDYLOARTHRITIS (AXSPA) AND PSORIATIC ARTHRITIS (PSA) STARTING TREATMENT WITH TARGETED THERAPY IN THE CZECH REPUBLIC. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1907.1-1908	2.4	0

249	FRI0255 BODY COMPOSITION IN SCLERODERMA PATIENTS IS ASSOCIATED WITH DISEASE ACTIVITY, SERUM LEVELS OF INFLAMMATORY CYTOKINES AND PARAMETERS OF NUTRITION AND LIPID METABOLISM. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 711.3-712	2.4	
248	OP0135 INHIBITION OF HSP90 REDUCES PROGRESSION OF DERMAL FIBROSIS AND INDUCES REGRESSION OF ESTABLISHED EXPERIMENTAL DERMAL FIBROSIS INDUCED BY BLEOMYCIN. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 87-88	2.4	
247	SAT0627-HPR SEXUAL QUALITY OF LIFE IN 39 FEMALE PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1273.2-1274	2.4	
246	AB0001 PLASMA miRNA PROFILE IN PATIENTS WITH HAND OSTEOARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1305.1-1305	2.4	
245	OP0136 THE INFLUENCE OF LONG-TERM EXERCISE AND IN VITRO EXERCISE-MIMICKING STIMULATION ON THE PRODUCTION OF MYOKINES AND CYTOKINES IN MYOTUBES OF PATIENTS WITH CHRONIC IDIOPATHIC INFLAMMATORY MYOPATHIES. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 88.2-88	2.4	
244	OP0138 CLUSTERIN ASSOCIATES WITH DISEASE MECHANISMS AND INFLAMMATION IN MYOSITIS PATIENTS. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 89.2-89	2.4	
243	THU0358 NEGATIVE CHANGES OF BODY COMPOSITION IN MYOSITIS PATIENTS AND THEIR ASSOCIATION WITH DISEASE SPECIFIC CHARACTERISTICS, PHYSICAL ACTIVITY AND NUTRITIONAL STATUS.. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 410.3-410	2.4	
242	FRI0262 INCREASED PLASMA LEVELS OF HSP90 ARE ASSOCIATED WITH MORE SEVERE LUNG AND SKIN INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 715-716	2.4	
241	Chemokine and Cytokine Profiles in Patients with Hand Osteoarthritis. <i>Biomolecules</i> , <b>2020</b> , 11,	5.9	2
240	Identification of a novel autoantigen eukaryotic initiation factor 3 associated with polymyositis. <i>Rheumatology</i> , <b>2020</b> , 59, 1026-1030	3.9	11
239	Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry. <i>Expert Opinion on Biological Therapy</i> , <b>2020</b> , 20, 183-192	5.4	3
238	Cytokines and inflammatory mediators as promising markers of polymyositis/dermatomyositis. <i>Current Opinion in Rheumatology</i> , <b>2020</b> , 32, 534-541	5.3	4
237	EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1423-1431	2.4	3
236	How Imaging Can Assist with Diagnosis and Monitoring of Disease in Myositis. <i>Current Rheumatology Reports</i> , <b>2020</b> , 22, 62	4.9	2
235	239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018. <i>Neuromuscular Disorders</i> , <b>2020</b> , 30, 70-92	2.9	53
234	Pro-inflammatory S100A11 is elevated in inflammatory myopathies and reflects disease activity and extramuscular manifestations in myositis. <i>Cytokine</i> , <b>2019</b> , 116, 13-20	4	11
233	Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 996-1002	2.4	48
232	Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial <i>Arthritis Research and Therapy</i> , <b>2019</b> , 21, 101	5.7	34

231	Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. <i>Journal of Autoimmunity</i> , <b>2019</b> , 101, 48-55	15.5	96
230	Serum visfatin levels in patients with axial spondyloarthritis and their relationship to disease activity and spinal radiographic damage: a cross-sectional study. <i>Rheumatology International</i> , <b>2019</b> , 39, 1037-1043	3.6	4
229	Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1472-1479	2.4	2
228	Idiopathic Inflammatory Myopathies. <i>Rheumatic Disease Clinics of North America</i> , <b>2019</b> , 45, 569-581	2.4	25
227	Arthritis in Idiopathic Inflammatory Myopathies. <i>Current Rheumatology Reports</i> , <b>2019</b> , 21, 70	4.9	2
226	Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study. <i>Rheumatology International</i> , <b>2019</b> , 39, 469-478	3.6	15
225	Effect of CTLA4-Ig (abatacept) treatment on T cells and B cells in peripheral blood of patients with polymyositis and dermatomyositis. <i>Scandinavian Journal of Immunology</i> , <b>2019</b> , 89, e12732	3.4	0
224	Real world use of secukinumab for treatment of axial spondyloarthritis and psoriatic arthritis: nationwide results from the ATTRA registry. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37, 342-343	2.2	7
223	S100A11 (calgizzarin) is released by circulating mononuclear cells and its elevated plasma levels distinguish systemic lupus erythematosus patients from healthy individuals. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37, 338-339	2.2	1
222	Cigarette smoking and clinical response to certolizumab pegol treatment in Hungarian, Czech, and Slovak patients with rheumatoid arthritis: 104-week data from the CIMDORA prospective, non-interventional study. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37, 1010-1018	2.2	1
221	Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein. <i>Clinical Rheumatology</i> , <b>2018</b> , 37, 2055-2062	3.9	12
220	Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 495-499	2.4	6
219	Splicing variant of augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 602-611	2.4	31
218	Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor $\beta$ Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , <b>2018</b> , 70, 679-689	9.5	53
217	Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 55-62	2.4	61
216	Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , <b>2018</b> , 70, 40-48	9.5	75
215	The EuroMyositis registry: an international collaborative tool to facilitate myositis research. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 30-39	2.4	105
214	A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , <b>2018</b> , 70, 49-59	9.5	58

213	Genetic background may contribute to the latitude-dependent prevalence of dermatomyositis and anti-TIF1- $\alpha$ autoantibodies in adult patients with myositis. <i>Arthritis Research and Therapy</i> , <b>2018</b> , 20, 117	5.7	10
212	Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1 positive polymyositis and dermatomyositis. <i>Arthritis Research and Therapy</i> , <b>2018</b> , 20, 158	5.7	12
211	Response to: Antisynthetase syndrome or what else? Different perspectives indicate the need for new classification criteria by Cavagna. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, e51	2.4	1
210	Idiopathic inflammatory myopathies. <i>Vnitřní Lekarství</i> , <b>2018</b> , 64, 155-163	0.3	0
209	Lower serum clusterin levels in patients with erosive hand osteoarthritis are associated with more pain. <i>BMC Musculoskeletal Disorders</i> , <b>2018</b> , 19, 264	2.8	12
208	The role of imaging in evaluating patients with idiopathic inflammatory myopathies. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36 Suppl 114, 74-81	2.2	3
207	A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 51-57	2.4	157
206	Immune-Array Analysis in Sporadic Inclusion Body Myositis Reveals HLA-DRB1 Amino Acid Heterogeneity Across the Myositis Spectrum. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 1090-1099	9.5	24
205	A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 1020-1030	2.4	91
204	EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 491-496	2.4	125
203	International collaboration including patients is essential to develop new therapies for patients with myositis. <i>Current Opinion in Rheumatology</i> , <b>2017</b> , 29, 234-240	5.3	4
202	Calgizzarin (S100A11): a novel inflammatory mediator associated with disease activity of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , <b>2017</b> , 19, 79	5.7	24
201	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 911-922	9.5	36
200	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 898-910	9.5	33
199	2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 801-804	2.4	65
198	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 911-922	2.4	24
197	Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients. <i>Rheumatology and Therapy</i> , <b>2017</b> , 4, 57-69	4.4	10
196	2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 1955-1964	2.4	393



195	Association between circulating miRNAs and spinal involvement in patients with axial spondyloarthritis. <i>PLoS ONE</i> , <b>2017</b> , 12, e0185323	3.7	25
194	52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis. <i>Rheumatology</i> , <b>2017</b> , 56, 2093-2101	3.9	40
193	Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> ,	2.4	67
192	MRI scoring methods used in evaluation of muscle involvement in patients with idiopathic inflammatory myopathies. <i>Current Opinion in Rheumatology</i> , <b>2017</b> , 29, 623-631	5.3	15
191	EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. <i>RMD Open</i> , <b>2017</b> , 3, e000507	5.9	66
190	2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 2271-2282	9.5	210
189	Interleukin-20 is triggered by TLR ligands and associates with disease activity in patients with rheumatoid arthritis. <i>Cytokine</i> , <b>2017</b> , 97, 187-192	4	10
188	2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects. <i>Rheumatology</i> , <b>2017</b> , 56, 1884-1893	3.9	23
187	Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study. <i>PLoS ONE</i> , <b>2017</b> , 12, e0183420	3.7	19
186	A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 96-102	2.4	47
185	A3.10 Serum calprotectin is elevated in patients with early rheumatoid arthritis but not in patients at risk of developing rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, A36.1-A36	2.4	
184	Systematic protein-protein interaction and pathway analyses in the idiopathic inflammatory myopathies. <i>Arthritis Research and Therapy</i> , <b>2016</b> , 18, 156	5.7	4
183	Confirmation on the immunogenicity assay used in the SB4 phase III study: response to the comments by Meacci et al. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, e40	2.4	8
182	A6.12 Physiological evidence for diversification of IFN $\alpha$ and IFN $\gamma$ mediated response programs in different autoimmune diseases. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, A52.1-A52	2.4	
181	A9.04 SNPS in the baf gene are associated with increased risk of anti-jo-1-positivity and high serum baf levels in patients with myositis. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, A71.2-A72	2.4	
180	A10.17 Interleukin-20 serum levels correlate with disease activity in rheumatoid arthritis patients and decrease in response to rituximab treatment. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, A79.2-A79	2.4	
179	SAT0068 Circulating MIR-126 Is A Marker of Disease Activity in Patients with Early RA but Does Not Differentiate Patients at Risk of Developing RA. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 689.2-689	2.4	
178	Response to: Reporting of potential immunogenicity with biologic drugs: clarity and accuracy required by Moots et al. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, e25	2.4	5

177	A8.06 MicroRNA-125b expression in PBMCS is inversely associated with disease activity in patients with early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, A67.1-A67	2.4	
176	AB0599 Interleukin-35 in Idiopathic Inflammatory Myopathies. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 1109.2-1109	2.4	
175	Physiological evidence for diversification of IFN $\beta$ and IFN $\gamma$ mediated response programs in different autoimmune diseases. <i>Arthritis Research and Therapy</i> , <b>2016</b> , 18, 49	5.7	21
174	MicroRNA-125b: association with disease activity and the treatment response of patients with early rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , <b>2016</b> , 18, 124	5.7	35
173	Disease specificity of autoantibodies to cytosolic 5 $\alpha$ -nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 696-701	2.4	90
172	The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 795-810	2.4	540
171	Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 1558-66	2.4	85
170	Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission. <i>PLoS ONE</i> , <b>2016</b> , 11, e0165498	3.7	8
169	SAT0240 Snps in The Baff Gene Are Associated with Increased Risk of Anti-Jo-1-Positivity and High Serum BAFF Levels in Patients with Myositis. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 755.2-755	2.4	
168	AB0952 Serum Visfatin and Resistin, but Not Adiponectin or Leptin, Are Associated with Ultrasound Synovitis in Patients with Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 1227.1-1227	2.4	
167	FRI0216 Long-Term Safety and Efficacy of Mavrilimumab, A Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-Alpha Monoclonal Antibody, in Patients with Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 510.1-510	2.4	1
166	A9.02 Heat shock protein 90 plasma levels correlate with disease activity, skeletal muscle, lung and heart involvement in idiopathic inflammatory myopathies. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, A70.2-A71	2.4	
165	Expression and Regulation of PIWIL-Proteins and PIWI-Interacting RNAs in Rheumatoid Arthritis. <i>PLoS ONE</i> , <b>2016</b> , 11, e0166920	3.7	15
164	Autoantibody Specificities and Type I Interferon Pathway Activation in Idiopathic Inflammatory Myopathies. <i>Scandinavian Journal of Immunology</i> , <b>2016</b> , 84, 100-9	3.4	18
163	Difference between SB4 and reference etanercept in the hepatobiliary disorders not considered to be caused by SB4: response to letter by Scheinberg and Azevedo. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, e65	2.4	8
162	SAT0146 Earth Explorer 2, A Phase IIB Exploratory Study Evaluating Efficacy and Safety of Mavrilimumab, A Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-Alpha Monoclonal Antibody, and The Tumor Necrosis Factor Antagonist Golimumab in Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 717.2-718	2.4	2
161	Response to: Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration by Marshall et al. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, e38	2.4	6
160	THU0150 Long-Term Safety and Efficacy of SB4 (Etanercept Biosimilar) in Patients with Rheumatoid Arthritis: Comparison between Continuing SB4 and Switching from Etanercept Reference Product To SB4. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 236.1-236	2.4	11



159	Response to: Lower anti-drug antibodies with etanercept biosimilar: Can Ctrough explain the differences? By Shah. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, e61	2.4	1
158	Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study. <i>Autoimmunity Reviews</i> , <b>2016</b> , 15, 983-93	13.6	76
157	Increased visfatin levels are associated with higher disease activity in anti-Jo-1-positive myositis patients. <i>Clinical and Experimental Rheumatology</i> , <b>2016</b> , 34, 222-9	2.2	1
156	Interleukin-35 is upregulated in systemic sclerosis and its serum levels are associated with early disease. <i>Rheumatology</i> , <b>2015</b> , 54, 2273-82	3.9	14
155	OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 2123-9	2.4	30
154	High levels of metastasis-inducing S100A4 protein and treatment outcome in early rheumatoid arthritis: data from the PERAC cohort. <i>Biomarkers</i> , <b>2015</b> , 20, 47-51	2.6	9
153	The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region. <i>RMD Open</i> , <b>2015</b> , 1, e000044	5.9	13
152	Increasing incidence of immune-mediated necrotizing myopathy: single-centre experience. <i>Rheumatology</i> , <b>2015</b> , 54, 2010-4	3.9	45
151	Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes. <i>Genes and Immunity</i> , <b>2015</b> , 16, 470-80	4.4	75
150	Dr. Vencovskij et al reply. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 1061	4.1	
149	OP0034 Efficacy and Safety of Mavrilimumab, A Fully Human GM-CSF-Alpha Monoclonal Antibody in Patients with Rheumatoid Arthritis: Primary Results from the Earth Explorer 1 Study. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 78.1-78	2.4	
148	THU0056 Expression of Piwi-interacting RNA in Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 212.2-212	2.4	
147	SAT0436 Abatacept in the Treatment of Adult Dermatomyositis and Polymyositis: Artemis, a Randomized, Treatment Delayed-Start Trial. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 817.3-818	2.4	2
146	FRI0128 A Phase III Randomised, Double-Blind Clinical Study Comparing SB4, An Etanercept Biosimilar, With Etanercept Reference Product (Enbrel®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (24-Week Results). <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 147.3-148	2.4	2
145	Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 245	5.7	19
144	Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 341	5.7	12
143	A2.33 Haplotype TTTT in the BAFF gene is associated with idiopathic inflammatory myopathies in HLA-DRB1*03 negative patients. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, A29.2-A29	2.4	
142	SAT0189 Rapid Onset of Clinical Benefit in Patients with RA Treated with Mavrilimumab, A Fully Human Monoclonal Antibody Targeting GM-CSF-ALPHA: Subanalysis of the Phase IIB Earth Explorer 1 Study. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 723.3-724	2.4	

141	A6.26 Analysis of circulating mirnas in patients with axial spondyloarthritis with different spinal involvement. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, A66.1-A66	2.4	1
140	FRI0435 Interleukin-35 is Overexpressed in Systemic Sclerosis and its Serum Levels are Elevated in Early Disease. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 584.3-585	2.4	
139	A3.10 Plasma levels of heat shock protein 90 correlate with disease activity, lung involvement and skin fibrosis in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, A35.1-A35	2.4	1
138	SAT0456 Heat Shock Protein 90 Plasma Levels Correlate with Disease Activity, Lung Involvement and Skin Fibrosis in Systemic Sclerosis. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 825.3-826	2.4	
137	SAT0250 A Tailored Approach to Reduce Dose of Anti-TNF Drugs is Equally Effective and Less Costly Than Standard Dosing in Patients with Ankylosing Spondylitis Over Two Years: A Propensity Score-Matched Cohort Study. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 749.2-749	2.4	2
136	FRI0592 Serum Calprotectin is Associated with Ultrasound-Determined Active Synovitis in Patients with Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 642.2-642	2.4	
135	Progranulin Is Associated with Disease Activity in Patients with Rheumatoid Arthritis. <i>Mediators of Inflammation</i> , <b>2015</b> , 2015, 740357	4.3	23
134	THU0127 Development of Draft Criteria for Arthralgia that is Clinically Suspect for Progression to Rheumatoid Arthritis; Results of Phase 1. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 240.1-240	2.4	1
133	Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 252	5.7	42
132	Pro-inflammatory effects of interleukin-35 in rheumatoid arthritis. <i>Cytokine</i> , <b>2015</b> , 73, 36-43	4	39
131	Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies. <i>Journal of Clinical Investigation</i> , <b>2015</b> , 125, 4612-24	15.9	27
130	Interleukin 35 Synovial Fluid Levels Are Associated with Disease Activity of Rheumatoid Arthritis. <i>PLoS ONE</i> , <b>2015</b> , 10, e0132674	3.7	24
129	Inflammatory myopathy associated with statins: report of three cases. <i>Modern Rheumatology</i> , <b>2014</b> , 24, 366-71	3.3	5
128	The metastasis-associated protein S100A4 promotes the inflammatory response of mononuclear cells via the TLR4 signalling pathway in rheumatoid arthritis. <i>Rheumatology</i> , <b>2014</b> , 53, 1520-6	3.9	45
127	OP0289 A Prospective, Randomized, Open-Label, Assessor-Blind, Multicenter Study of Efficacy and Safety of Combined Treatment of Methotrexate + Glucocorticoids versus Glucocorticoids Alone in Patients with Polymyositis and Dermatomyositis (Prometheus Trial). <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 171.1-171	2.4	2
126	OP0235 Genetic Risk Factors in Idiopathic Inflammatory Myopathies Are Shared with Other Autoimmune Disorders in European Populations. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 151.1-151	2.4	
125	FRI0520 Association Study of the BAFF Genetic Variations in Two Independent Cohorts with Idiopathic Inflammatory Myopathies. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 575.3-576	2.4	
124	AB0009 Association of MHC Haplotypes with Idiopathic Inflammatory Myopathy in Cohort of Czech Patients. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 806.3-806	2.4	

123	AB0163 Comprehensive Analysis of Circulating Mirnas in Patients with Axial Spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 856.4-857	2.4	
122	SAT0565 The Expression and Regulation of the Argonaute Protein Family Member PIWIL4 in RA. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 795.1-795	2.4	
121	A3.29 Micro-RNA molecules are clearly involved in pathogenesis of idiopathic inflammatory myopathy. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, A53.3-A54	2.4	
120	Decreased circulating visfatin is associated with improved disease activity in early rheumatoid arthritis: data from the PERAC cohort. <i>PLoS ONE</i> , <b>2014</b> , 9, e103495	3.7	17
119	AB0075 Calgizzarin (S100A11) is Up-Regulated in Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 829.1-829	2.4	
118	THU0528 Decrease in Circulating Visfatin Levels is Associated with Disease Activity Improvement in Early Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 366.1-366	2.4	1
117	A1.48 Enhanced expression of CD11c on non-classical CD16+ peripheral blood monocytes in early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, A20.2-A21	2.4	1
116	SAT0349 A Tailored Approach to Reduce Dose of Anti-TNF Drugs is Equally Effective, but Substantially Less Costly than Standard Dosing in Patients with Ankylosing Spondylitis over One Year: A Matched Observational Study. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 719.1-719	2.4	1
115	Arthritis in idiopathic inflammatory myopathy: clinical features and autoantibody associations. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 1133-9	4.1	18
114	The metastasis promoting protein S100A4 levels associate with disease activity rather than cancer development in patients with idiopathic inflammatory myopathies. <i>Arthritis Research and Therapy</i> , <b>2014</b> , 16, 468	5.7	13
113	FRI0543 Pregnancy Outcome in Adult Juvenile Idiopathic Arthritis Patients Treated with Biologic Agents. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 583.2-583	2.4	1
112	Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 1898-904	2.4	140
111	Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country or wealth?. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 2010-21	2.4	71
110	The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trial. <i>Journal of the American Society of Hypertension</i> , <b>2014</b> , 8, 780-90		7
109	Genotyping of immune-related genetic variants identifies TYK2 as a novel associated locus for idiopathic inflammatory myopathies. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 1750-2	2.4	21
108	A3.30 Plasma level of HSP70 protein is increased in czech patients with idiopathic inflammatory myopathy. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, A54.1-A54	2.4	1
107	Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies. <i>Arthritis Research and Therapy</i> , <b>2014</b> , 16, 454	5.7	19
106	Pregnancy outcome in idiopathic inflammatory myopathy patients in a multicenter study. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 2492-4	4.1	19

105	Therapy of myositis: biological and physical. <i>Current Opinion in Rheumatology</i> , <b>2014</b> , 26, 704-11	5.3	29
104	Decrease in serum interleukin-21 levels is associated with disease activity improvement in patients with recent-onset rheumatoid arthritis. <i>Physiological Research</i> , <b>2014</b> , 63, 475-81	2.1	14
103	The role of resistin in inflammatory myopathies. <i>Current Rheumatology Reports</i> , <b>2013</b> , 15, 336	4.9	14
102	The level of fatty acid-binding protein 4, a novel adipokine, is increased in rheumatoid arthritis and correlates with serum cholesterol levels. <i>Cytokine</i> , <b>2013</b> , 64, 441-7	4	13
101	Seroprevalence and specificity of NMO-IgG (anti-aquaporin 4 antibodies) in patients with neuropsychiatric systemic lupus erythematosus. <i>Rheumatology International</i> , <b>2013</b> , 33, 259-63	3.6	31
100	SAT0151 Long-term safety of 4-weekly certolizumab pegol in rheumatoid arthritis: 5 year results from an open label extension study. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 71, 523.1-523	2.4	1
99	Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. <i>Arthritis and Rheumatism</i> , <b>2013</b> , 65, 3239-47		94
98	A10.3 Arthritis in Patients with Idiopathic Inflammatory Myopathies. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, A72.2-A72	2.4	1
97	A7.7 Different Genetic Background of Dermatomyositis and Polymyositis in a Single Centre Cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, A50.2-A50	2.4	
96	SAT0188 Clinical and Ultrasonographic Characteristics of Arthritis in Patients with Idiopathic Inflammatory Myopathies. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, A644.3-A645	2.4	1
95	FRI0186 Long-term safety and efficacy of 4-weekly certolizumab pegol monotherapy and combination therapy in rheumatoid arthritis: 5-year results from an open-label extension study. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, A435.1-A435	2.4	3
94	A7.11 Genetic Variation in Promoter Sequence of B-Cell-Activating Factor of the TNF Family (BAFF) in Patients with Idiopathic Inflammatory Myopathies (IIM). <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, A51.3-A52	2.4	2
93	THU0232 Pregnancy outcome in idiopathic inflammatory myopathy patients in a multicenter study. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 71, 233.3-234	2.4	
92	SAT0001 IFN signature is associated with autoantibody profiles in patients with myositis. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 71, 471.1-471	2.4	
91	SAT0023 Investigation of idiopathic inflammatory myopathy for shared genetic risk factors with other autoimmune disorders: Results of UK myonet. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 71, 478.3-479 <sup>4</sup>		
90	SAT0031 Anti-RO52 autoantibody epitope mapping in european cohort of myositis patients. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 71, 481.2-481	2.4	
89	SAT0105 Circulating MIR-223 is downregulated in SERA of patients with early RA after treatment with methotrexate. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 71, 506.1-506	2.4	
88	A4.15 Serum Levels of Visfatin and B-Cell Activating Factor of the TNF Family Correlate with Disease Activity in Patients with Myositis. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, A29.2-A29	2.4	

87	A7.3 Association of Circulating miR-223 and miR-16 with Disease Activity in Patients with Early Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, A48.3-A49	2.4	
86	A7.24 The Pentanucleotide Insertion in HSPA1B Gene is Associated with Idiopathic Inflammatory Myopathy. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, A56.2-A56	2.4	1
85	FRI0077 Levels of mir-16 in serum associate with response to therapy in patients with early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, A395.1-A395	2.4	
84	THU0253 ANTI-PM-SCL autoantibodies in polymyositis and dermatomyositis. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 71, 240.2-240	2.4	1
83	The expression profile of miR-23b is not altered in peripheral blood mononuclear cells of patients with idiopathic inflammatory myopathies. <i>F1000Research</i> , <b>2013</b> , 2, 223	3.6	1
82	Quantiferon TB Gold and tuberculin skin tests for the detection of latent tuberculosis infection in patients treated with tumour necrosis factor alpha blocking agents. <i>Clinical and Experimental Rheumatology</i> , <b>2013</b> , 31, 111-7	2.2	15
81	No effect of physiotherapy on the serum levels of adipocytokines in patients with ankylosing spondylitis. <i>Clinical Rheumatology</i> , <b>2012</b> , 31, 67-71	3.9	15
80	Adiponectin relation to skin changes and dyslipidemia in systemic sclerosis. <i>Cytokine</i> , <b>2012</b> , 58, 165-8	4	25
79	Resistin in idiopathic inflammatory myopathies. <i>Arthritis Research and Therapy</i> , <b>2012</b> , 14, R111	5.7	17
78	International cohort study of 73 anti-Ku-positive patients: association of p70/p80 anti-Ku antibodies with joint/bone features and differentiation of disease populations by using principal-components analysis. <i>Arthritis Research and Therapy</i> , <b>2012</b> , 14, R2	5.7	13
77	Inflammatory myopathy associated with statins: report of three cases. <i>Modern Rheumatology</i> , <b>2012</b> , 1	3.3	
76	Interaction of HLA-DRB1*03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case study. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 961-5	2.4	75
75	Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. <i>Rheumatology</i> , <b>2012</b> , 51, 1226-34	3.9	56
74	Low circulating Dickkopf-1 and its link with severity of spinal involvement in diffuse idiopathic skeletal hyperostosis. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 71-4	2.4	45
73	European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 4-12	2.4	355
72	Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature. <i>Medicine (United States)</i> , <b>2012</b> , 91, 206-211	1.8	74
71	Anti-Ro52 epitope mapping in inflammatory myopathies. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, A50.1-A50	2.4	
70	IFN signature is associated with autoantibody profiles in patients with myositis. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, A49.1-A49	2.4	



69	Pentosidine, an advanced glycation end-product, may reflect clinical and morphological features of hand osteoarthritis. <i>Open Rheumatology Journal</i> , <b>2012</b> , 6, 64-9	0.2	5
68	Novel adipokine fibroblast growth factor 21 is increased in rheumatoid arthritis. <i>Physiological Research</i> , <b>2012</b> , 61, 489-94	2.1	20
67	Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , <b>2011</b> , 13, R122	5.7	52
66	The level of serum visfatin (PBEF) is associated with total number of B cells in patients with rheumatoid arthritis and decreases following B cell depletion therapy. <i>Cytokine</i> , <b>2011</b> , 55, 116-21	4	24
65	Clinical trials roundup in idiopathic inflammatory myopathies. <i>Current Opinion in Rheumatology</i> , <b>2011</b> , 23, 605-11	5.3	6
64	Adipokine profile is modulated in subcutaneous adipose tissue by TNF $\alpha$ inhibitors in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 2054-6	2.4	8
63	The expression regulation of the HSPA1B gene in patients with myositis is not dependent on the presence of HLA-DRB1*03 risk allele. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, A19-A20	2.4	
62	Modulation of subcutaneous adipose tissue adipokines by TNF $\alpha$ blockade therapy in patients with inflammatory arthritides. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, A85-A85	2.4	
61	Serum levels of interferon $\gamma$ do not correlate with disease activity in patients with dermatomyositis/polymyositis. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 879-80	2.4	11
60	The metastasis promoting protein S100A4 is increased in idiopathic inflammatory myopathies. <i>Rheumatology</i> , <b>2011</b> , 50, 1766-72	3.9	33
59	Potential role of S100A4 in an immune response of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, A85-A85	2.4	
58	Serum levels of IFN $\gamma$ do not correlate with disease activity in patients with dermatomyositis/polymyositis. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, A89-A90	2.4	
57	Delays in assessment of patients with rheumatoid arthritis: variations across Europe. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 1822-5	2.4	88
56	Interrater reliability and aspects of validity of the myositis damage index. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 1272-6	2.4	18
55	Myositis associated autoantibodies detected using a novel recombinant protein blotting: clinical associations. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, A9-A10	2.4	1
54	Genetic variation in promoter sequence of B cell-activating factor gene is associated with increased risk of myositis development. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, A31-A31	2.4	
53	Metastasis-Promoting protein S100A4 (MTS1) upregulates production of proinflammatory cytokines via TLR-4. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, A38-A39	2.4	
52	2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 1580-8	2.4	2158

51	Vaspin and omentin: new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 1410-1	2.4	78
50	Polymorphism of the extrapituitary prolactin promoter and systemic sclerosis. <i>Rheumatology International</i> , <b>2010</b> , 30, 1691-3	3.6	9
49	Treatment-resistant inflammatory myopathy. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2010</b> , 24, 427-40	5.3	6
48	CD161 receptor participates in both impairing NK cell cytotoxicity and the response to glycans and vimentin in patients with rheumatoid arthritis. <i>Clinical Immunology</i> , <b>2010</b> , 136, 139-47	9	7
47	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 2582-91		182
46	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 2569-81		4825
45	Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 3154-60		50
44	Increased serum concentration of immune cell derived microparticles in polymyositis/dermatomyositis. <i>Immunology Letters</i> , <b>2010</b> , 128, 124-30	4.1	28
43	Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy. <i>Annals of the Rheumatic Diseases</i> , <b>2009</b> , 68, 1285-9	2.4	49
42	Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. <i>Annals of the Rheumatic Diseases</i> , <b>2009</b> , 68, 805-11	2.4	241
41	Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , <b>2009</b> , 68, 797-804	2.4	339
40	Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. <i>Annals of the Rheumatic Diseases</i> , <b>2009</b> , 68, 836-43	2.4	75
39	Metastasis-inducing S100A4 protein is associated with the disease activity of rheumatoid arthritis. <i>Rheumatology</i> , <b>2009</b> , 48, 1590-4	3.9	32
38	Prospective new biological therapies for rheumatoid arthritis. <i>Autoimmunity Reviews</i> , <b>2009</b> , 9, 102-7	13.6	107
37	Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA. <i>Clinical and Experimental Rheumatology</i> , <b>2009</b> , 27, 958-63	2.2	45
36	Reliability and validity of the myositis disease activity assessment tool. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 58, 3593-9		58
35	Quantiferon-TB Gold test in screening for latent tuberculosis before and during antitumour necrosis factor treatment. <i>Arthritis Research and Therapy</i> , <b>2007</b> , 9, P33	5.7	1
34	Endogenous HLA-DR-restricted presentation of the cartilage antigens human cartilage gp-39 and melanoma inhibitory activity in the inflamed rheumatoid joint. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 56, 2150-9		19

33	The role of MRI in the assessment of polymyositis and dermatomyositis. <i>Rheumatology</i> , <b>2007</b> , 46, 1174-9	3.9	149
32	Advanced glycation end-product pentosidine is not a relevant marker of disease activity in patients with rheumatoid arthritis. <i>Physiological Research</i> , <b>2007</b> , 56, 771-777	2.1	10
31	Radiographic progression of rheumatoid arthritis in patients from the Czech National Registry receiving infliximab treatment. <i>Clinical and Experimental Rheumatology</i> , <b>2007</b> , 25, 540-5	2.2	10
30	Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. <i>Annals of the Rheumatic Diseases</i> , <b>2006</b> , 65, 1635-8	2.4	217
29	Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen. <i>Annals of the Rheumatic Diseases</i> , <b>2006</b> , 65, 242-5	2.4	96
28	Rheumatoid arthritis: the goal rather than the health-care provider is key. <i>Lancet, The</i> , <b>2006</b> , 367, 450-2	4.0	11
27	The importance of cell surface RANKL in rheumatoid arthritis. <i>Arthritis Research</i> , <b>2005</b> , 7, P152		78
26	Citrullinated peptide-specific CD19+B cells are present in synovial tissue and peripheral blood of patients with rheumatoid arthritis. <i>Arthritis Research</i> , <b>2005</b> , 7, P149		78
25	A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2005</b> , 64, 64-9	2.4	71
24	International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. <i>Rheumatology</i> , <b>2004</b> , 43, 49-54	3.9	249
23	Therapeutic strategies in polymyositis and dermatomyositis. <i>Drug Discovery Today: Therapeutic Strategies</i> , <b>2004</b> , 1, 369-374		2
22	The expression of cyclooxygenase-1, cyclooxygenase-2 and 5-lipoxygenase in inflammatory muscle tissue of patients with polymyositis and dermatomyositis. <i>Clinical and Experimental Rheumatology</i> , <b>2004</b> , 22, 395-402	2.2	9
21	Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2003</b> , 62, 427-30	2.4	194
20	Expression of IgVH mRNAs in plasma cells derived from rheumatoid arthritis synovium detected by single-cell RT-PCR. <i>Arthritis Research</i> , <b>2003</b> , 5, 119		78
19	Polymorphism in the immunoglobulin VH gene V1-69 affects susceptibility to rheumatoid arthritis in subjects lacking the HLA-DRB1 shared epitope. <i>British Journal of Rheumatology</i> , <b>2002</b> , 41, 401-10		16
18	Tumour necrosis factor alpha G-->A -238 and G-->A -308 polymorphisms in juvenile idiopathic arthritis. <i>Rheumatology</i> , <b>2002</b> , 41, 223-7	3.9	64
17	Higher frequency of allele 2 of the interleukin-1 receptor antagonist gene in patients with juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , <b>2001</b> , 44, 2387-91		41
16	Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. <i>British Journal of Rheumatology</i> , <b>2001</b> , 40, 1262-73		226

15	Autoantibody profiles in the sera of European patients with myositis. <i>Annals of the Rheumatic Diseases</i> , <b>2001</b> , 60, 116-23	2.4	261
14	Immunological investigation in children with juvenile chronic arthritis. <i>Medical Science Monitor</i> , <b>2001</b> , 7, 99-104	3.2	6
13	The relative prevalence of dermatomyositis and polymyositis in Europe exhibits a latitudinal gradient. <i>Annals of the Rheumatic Diseases</i> , <b>2000</b> , 59, 141-2	2.4	71
12	Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. <i>Scandinavian Journal of Rheumatology</i> , <b>2000</b> , 29, 95-102	1.9	142
11	Identification of common epitopes on gliadin, enterocytes, and calreticulin recognised by antigliadin antibodies of patients with coeliac disease. <i>Gut</i> , <b>1999</b> , 44, 168-73	19.2	40
10	Primary Sjögren's syndrome in children and adolescents: proposal for diagnostic criteria. <i>Clinical and Experimental Rheumatology</i> , <b>1999</b> , 17, 381-6	2.2	58
9	IL-10 gene promoter polymorphisms in rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , <b>1998</b> , 27, 142-5	1.9	137
8	Effect of 1 year cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study. <i>Lupus</i> , <b>1998</b> , 7, 29-36	2.6	55
7	Somatic mutation and CDR3 length of immunoglobulin lambda variable region genes in the synovium of patients with rheumatoid arthritis. <i>Annals of the New York Academy of Sciences</i> , <b>1997</b> , 815, 319-23	6.5	2
6	Immunoglobulin variable region (IgV) gene expression in rheumatoid factors from monozygotic twins with rheumatoid arthritis. <i>Annals of the New York Academy of Sciences</i> , <b>1997</b> , 815, 324-6	6.5	1
5	Heterogenous nuclear RNP C1 and C2 core proteins are targets for an autoantibody found in the serum of a patient with systemic sclerosis and psoriatic arthritis. <i>Arthritis and Rheumatism</i> , <b>1997</b> , 40, 2172-7		21
4	Monozygotic rheumatoid arthritis twin pairs express similar levels of conserved immunoglobulin V gene in polyclonal rheumatoid factors irrespective of disease status. <i>Scandinavian Journal of Immunology</i> , <b>1995</b> , 42, 147-57	3.4	7
3	Heterogeneity of disease phenotype in monozygotic twins concordant for rheumatoid arthritis. <i>Rheumatology</i> , <b>1995</b> , 34, 215-20	3.9	15
2	Clinical associations of IgG antibodies to the ribonucleoprotein p67 polypeptide in patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>1992</b> , 51, 1313-7	2.4	3
1	Clinical-morphological correlation of polymyositis and dermatomyositis. <i>Scandinavian Journal of Rheumatology</i> , <b>1987</b> , 67, 32-5	1.9	3